US Patent Issued to University of Washington, ABACUS BIOSCIENCE on April 29 for "Therapeutic vaccine for Hepatitis B virus (HBV) using the HBV PreS1 and/or PreS2, and/or S-HBsAg regions of the HBV envelope protein" (Washington Inventors)

ALEXANDRIA, Va., June 9 -- United States Patent no. 12,285,482, issued on April 29, was assigned to University of Washington (Seattle) and ABACUS BIOSCIENCE INC. (Sammamish, Wash.).

"Therapeutic vaccine for Hepatitis B virus (HBV) using the HBV PreS1 and/or PreS2, and/or S-HBsAg regions of the HBV envelope protein" was invented by Edward A. Clark (Seattle), Che-Leung Law (Seattle), Deborah Fuller (Seattle) and Michael Gale (Seattle).

According to the abstract* released by the U.S. Patent & Trademark Office: "Compositions including a CD180 binding ligand a linked Hepatitis B antigen and their use are disclosed. The Hepatitis B antigen includes Hepatitis B virus pre-S1 and/or pre-S2 region of the HBV envelope protein (HBVpreS1/S2Ag), L-HBsA...